Literature DB >> 23968618

Metrics survey of industry-sponsored clinical trials in Canada and comparator jurisdictions between 2005 and 2010.

Jean-Marie Leclerc1, Normand Laberge, Jean Marion.   

Abstract

Industry-sponsored clinical trials play a key role in the development of therapies. This survey suggests that between 2005 and 2010, research-based pharmaceutical firms worldwide initiated fewer trials and recruited fewer subjects annually. In contrast, at the country level, the clinical trial activity of such firms increased in emerging countries and in Japan. Canada's trend in the number of new trials followed that of the global industry, but the trend in new sites and newly recruited subjects fell below the global rate. Informal comparisons point to potential issues for Canada in such areas as site capacity, cost per subject and time to first subject-in. When compared to certain Western European countries and the United States, Canada remained well positioned on a number of metrics. Nonetheless, Canada faces mounting challenges from both traditional locations and emerging countries and may require coordinated efforts to remain a place of choice to conduct trials.
Copyright © 2012 Longwoods Publishing.

Mesh:

Year:  2012        PMID: 23968618      PMCID: PMC3517875     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  6 in total

1.  Boilerplate being tested for clinical trials agreements.

Authors:  Lauren Vogel
Journal:  CMAJ       Date:  2011-10-03       Impact factor: 8.262

2.  The paradoxical problem with multiple-IRB review.

Authors:  Jerry Menikoff
Journal:  N Engl J Med       Date:  2010-10-13       Impact factor: 91.245

3.  Ethical and scientific implications of the globalization of clinical research.

Authors:  Seth W Glickman; John G McHutchison; Eric D Peterson; Charles B Cairns; Robert A Harrington; Robert M Califf; Kevin A Schulman
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

4.  Clinical trials: the balance between protecting participants and promoting drug and product development.

Authors:  Miriam Shuchman
Journal:  CMAJ       Date:  2009-03-17       Impact factor: 8.262

5.  Reflections on the Innovative Medicines Initiative.

Authors:  Michel Goldman
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

6.  Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.

Authors:  Raphael Saginur; Susan F Dent; Lisa Schwartz; Ronald Heslegrave; Sid Stacey; Janet Manzo
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

  6 in total
  1 in total

1.  Trends in Canadian respiratory clinical trials from 2001 to 2011.

Authors:  Claire Tacon; Hina Abbas; Shiyuan Zhang; Barbara Nicholls; Glenn Crater; Zhen Su
Journal:  Can Respir J       Date:  2013-12-23       Impact factor: 2.409

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.